Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 6;11:8229–8238. doi: 10.2147/CMAR.S213931

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Shi et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Intracellular ROS changes induced by eltrombopag (EP) and/or decitabine (DAC) in myeloid leukemia cells. (A) Intracellular ROS levels in K562 cells following different doses of EP and/or DAC treatment were examined by flow cytometry. (B) Comparison of the ROS alterations in K562 cells cultured with EP and/or DAC. (C) Intracellular ROS levels in THP-1 cells following different doses of EP and/or DAC treatment were examined by flow cytometry. (D) Comparison of the ROS alterations in THP-1 cells incubated with EP and/or DAC. Data are represented as the mean ± SD (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05).